What is HC Wainwright’s Estimate for JSPR FY2029 Earnings?

Jasper Therapeutics, Inc. (NASDAQ:JSPR) – Analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Jasper Therapeutics in a report released on Wednesday, January 8th. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings per share of ($10.81) for the year. HC Wainwright currently has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Jasper Therapeutics’ current full-year earnings is ($4.47) per share.

Other equities analysts have also issued research reports about the stock. BMO Capital Markets assumed coverage on shares of Jasper Therapeutics in a report on Friday, December 6th. They set an “outperform” rating and a $63.00 target price on the stock. JMP Securities restated a “market outperform” rating and set a $70.00 target price on shares of Jasper Therapeutics in a report on Monday, January 6th. Finally, Royal Bank of Canada reduced their target price on shares of Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating on the stock in a report on Thursday. Ten research analysts have rated the stock with a buy rating, According to data from MarketBeat, Jasper Therapeutics presently has an average rating of “Buy” and a consensus price target of $67.75.

Jasper Therapeutics Trading Up 0.9 %

NASDAQ:JSPR opened at $7.05 on Friday. The firm has a market capitalization of $105.76 million, a price-to-earnings ratio of -1.49 and a beta of 2.18. The firm’s fifty day simple moving average is $21.09 and its 200 day simple moving average is $20.16. Jasper Therapeutics has a twelve month low of $6.57 and a twelve month high of $31.01.

Institutional Investors Weigh In On Jasper Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Samsara BioCapital LLC increased its position in shares of Jasper Therapeutics by 11.4% in the 3rd quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock worth $10,997,000 after purchasing an additional 59,642 shares during the last quarter. Wellington Management Group LLP bought a new stake in shares of Jasper Therapeutics in the 3rd quarter worth about $447,000. Ally Bridge Group NY LLC grew its position in shares of Jasper Therapeutics by 82.7% during the 3rd quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock valued at $7,514,000 after buying an additional 180,852 shares during the last quarter. Braidwell LP bought a new stake in shares of Jasper Therapeutics during the 3rd quarter valued at about $9,091,000. Finally, FMR LLC bought a new stake in shares of Jasper Therapeutics during the 3rd quarter valued at about $722,000. Institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.